A Third Anti-Sars-Cov2 mRNA Dose Does Not Overcome the Pejorative Impact of Anti-CD20 Therapy and/or Low Immunoglobulin Level in CLL/Lymphoma Patients

Introduction: Patients with lymphoma and chronic lymphocytic leukemia (CLL) share immune-deficiencies due to the biological features of these diseases per se and to their treatments. They are at risk to develop severe and/or prolonged forms of Covid-19. The efficacy of vaccination against COVID in l...

Descripción completa

Detalles Bibliográficos
Autores principales: Chbat, Maureen, Kohn, Milena, Merabet, Fatiha, Roupie, Anne-Laure, Lombion, Naelle, Guemriche, Amina, Marque-Juillet, Stéphanie, Raggueneau, Victoria, Osman, Jennifer, Spentchian, Marc, Delord, Marc, Rigaudeau, Sophie, Besson, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
642.Chronic Lymphocytic Leukemia: Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701562/
http://dx.doi.org/10.1182/blood-2021-150298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701562/
http://dx.doi.org/10.1182/blood-2021-150298

Ejemplares similares